Interv Akut Kardiol. 2018;17(3):169-172 | DOI: 10.36290/kar.2018.018

Edoxaban – its properties and role in antithrombotic prophylaxis in atrial fibrillation

Michal Černošek1,3, Martin Fiala1,2
1 Centrum kardiovaskulární péče, Neuron Medical, Brno
2 Interní kardiologická klinika, Fakultní nemocnice, Brno
3 Interní oddělení, Nemocnice Prostějov, Středomoravská nemocniční, a.s., Prostějov

Anticoagulation is an integral part of comprehensive care of patients with atrial fibrillation. In addition to vitamin K antagonists(VKA) used for years, more recently novel anticoagulant drugs have been increasingly prevailing, with edoxaban being the latestto have been approved for use. It is a drug with a favourable pharmacological profile, simple dosing schedule, minimal seriousinteractions, and efficacy confirmed by large randomized trials. Moreover, the safety and efficacy of edoxaban has been shownin the population of elderly patients as well as in those undergoing electrical cardioversion.

Keywords: edoxaban, atrial fibrillation, tromboembolism

Received: September 3, 2018; Accepted: September 3, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Černošek M, Fiala M. Edoxaban – its properties and role in antithrombotic prophylaxis in atrial fibrillation. Interv Akut Kardiol. 2018;17(3):169-172. doi: 10.36290/kar.2018.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. SPC - souhrn údajů o přípravku Lixiana - 2016.
    2. Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther 2016; 5: 1-18. Go to original source... Go to PubMed...
    3. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-1393. Go to original source... Go to PubMed...
    4. SPC - souhrn údajů o přípravku Eliquis, SPC - souhrn údajů o přípravku xarelto - 2016.
    5. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015; 36: 2239-2245. Go to original source... Go to PubMed...
    6. Levy JH, Douketis J, Weitz JI, Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018 May; 15(5): 273-281. Go to original source... Go to PubMed...
    7. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2094. Go to original source...
    8. Kato ET, Guigliano RP, Ruff CT, et al. Efficacy and safety of edoxaba in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 1016; 20: 5(5). Go to original source...
    9. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104(3): 633-641. Go to original source... Go to PubMed...
    10. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415. Go to original source... Go to PubMed...
    11. R. Čihák et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology, Cor et Vasa 2016; 58: e636-e683. Go to original source...
    12. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2016; 37: 2893-2862. Go to original source... Go to PubMed...
    13. James D, Douketis MD, Alex C. Spyropoulos MD, Scott Kaatz DO, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation N Engl J Med 2015; 373: 823-833. Go to original source...
    14. Cappato R, Marchlinski FE, Hohnloser SH, et al. VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-1811. Go to original source... Go to PubMed...
    15. Goette JL, Merino M, Ezekowitz, et al. Edoxaban versus enoxaparin / warfarin in subjects undergoing cardioversion of atrial fibrillation: the randomised (ENSURE-AF) study, Lancet 2016; 388: 1995-2003. Go to original source...
    16. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. Circ J 2015, 79:1486-1495. Go to original source... Go to PubMed...
    17. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015; 17: 1197-1214. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.